Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As HfiledCriticalLundbeck & Co As H
Priority to UY28789ApriorityCriticalpatent/UY28789A1/en
Publication of UY28789A1publicationCriticalpatent/UY28789A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Abstract
Se describen partículas cristalinas de oxalato de escitalopram que tienen o bien una amplia distrubución de tamano de partícula o comprenden por lo menos 0,01 % (p/p) de Z-4-(4-dimetilamino-1-(4-fluorfenil)-but-1-enilo)-3-hidroxi-metil-benzonitrilo, apropiadas para ser usadas en compresión directa. También se describe una nueva forma de dosificación farmacéutica unitario que contiene dichas partículas cristalinas de oxalato de escitalopram como también métodos de manufactura de las mismas. Finalmente la invención provee un método para la reducción de la cantidad de hidroxilo que contiene impurezas en una solución de citalopram o escitalopram.Crystalline particles of escitalopram oxalate are described which have either a wide particle size distribution or comprise at least 0.01% (w / w) of Z-4- (4-dimethylamino-1- (4-fluorphenyl) -but-1-enyl) -3-hydroxy-methyl-benzonitrile, suitable for use in direct compression. A new dosage unit dosage form containing said crystalline particles of escitalopram oxalate as well as manufacturing methods thereof is also described. Finally, the invention provides a method for reducing the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram.
COMPOUNDS DERIVED FROM PURINA REPLACED WITH OTHER HETEROCICLICAL SYSTEMS; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF AN INFLAMMATORY OR OBSTRUCTIVE DISEASE OF THE RESPIRATORY ROADS.
compounds, composition thereof, method of antagonizing one or more aspartic proteases and method for treating or ameliorating an aspartic protease-mediated disorder
COMPOUNDS DERIVED FROM SUBSTITUTED ISOXAZOLINS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF A DISEASE CAUSED BY AN INCREASE IN THE CELL PROLIFERATION.
Substituted 1,3-dihydro-5-isobenzofurancarbonitrile derivative compounds, selective serotonin reuptake inhibitors; pharmaceutical composition; preparation procedure; Useful in the treatment and / or prevention of premature ejaculation.
AMORPHY AND CRYSTALLINE FORM OF THE OXYM OF E-1- (4 - ((1R, 2S, 3R) -1,2,3,4-TETRAHYDROXIBUTIL) -1H-IMIDAZOL-2-IL) -ETANONA; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT, CONTROL OR PREVENT AN ILLNESS OR AN AUTOIMMUNE OR INFLAMMATORY DISORDER.
Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.